Bedrijfsoverzicht
QT Imaging Holdings, Inc. is a specialized entity dedicated to the research, development, and commercialization of body imaging systems that utilize low-frequency sound waves for the detection, diagnosis, monitoring, and treatment of various diseases within the United States and international markets. The company operates within the Healthcare sector, specifically focusing on the Medical Devices industry, which positions it to capitalize on advancements in diagnostic technology and medical infrastructure investments. Its operational scale is characterized by a market capitalization of $83.21M, annual revenue of $18.93M, and an employee base of 31 individuals. These valuation and revenue figures indicate that the company functions as a small-cap biotech or medical device firm, likely in a stage where capital allocation focuses heavily on product development and market penetration rather than established mass-market dominance.
Financiële gezondheid
QT Imaging Holdings, Inc. reported a total revenue of $18.93M over the trailing twelve months, yet this generated a net income of -$21.083M, revealing a significant gap that underscores a cost structure where expenses vastly exceed operational income. The company's EBITDA stands at -$4.306M, further highlighting that the business is currently burning cash to fund its expansion or research initiatives. Free cash flow is reported at -$8.5455M, which indicates a lack of immediate financial flexibility and suggests the firm relies on external capital sources or existing cash reserves to sustain operations. The gross margin sits at 45.4%, demonstrating that the company retains a substantial portion of revenue after direct production costs, which is typical for high-tech medical device manufacturers. However, the operating margin is negative at -8.5%, and the profit margin is severely depressed at -111.4%, indicating that overhead costs and R&D expenditures are consuming more than the gross profit generated. The balance sheet shows a cash position of $10.41M against a debt load of $5.24M, resulting in a debt-to-equity ratio of 81.36%. While the company holds more cash than debt, the high debt-to-equity ratio suggests a leveraged capital structure that could be risky if cash flows do not improve soon. The current ratio is 2.81, which signifies a strong short-term liquidity position, as the company possesses nearly three times the liquid assets required to cover its current liabilities. Return on Equity and Return on Assets are listed as N/A and -19.1% respectively, with the negative ROA revealing that the company's assets are currently generating value that is insufficient to cover interest and operational costs.
Waarderingsbeoordeling
Trailing P/E and Forward P/E ratios are both listed as N/A, which implies that traditional earnings-based valuation models are not applicable due to the company's consistent losses and lack of positive net income available to shareholders. Despite the absence of a price-to-earnings metric, the price-to-book ratio is 12.75, suggesting that the market values the company at a significant premium relative to its book value, likely anticipating future growth or proprietary technology worth far more than the tangible assets recorded on the balance sheet. The price-to-sales ratio stands at 4.40, while the EV/EBITDA is -18.12; these alternative metrics suggest that investors are pricing the stock based on revenue generation potential rather than current profitability, a common practice in the early stages of medical device development. The 52-week high is $46.05 and the 52-week low is $4.90, providing a wide trading range that reflects high investor sentiment volatility. Without the current share price explicitly provided in the facts, the exact percentage deviation from the high or low cannot be calculated, but the wide spread between the high and low indicates significant price discovery and potential volatility for the asset. The beta value is -0.09, which is an anomalous statistic that technically implies an inverse correlation to the broader market, though in practice, such a low or negative beta for a small-cap stock often indicates that price movements are idiosyncratic and decoupled from general market trends.
Growth & Income
Revenue growth year-over-year is reported at 877.2%, indicating an explosive expansion in top-line sales, whereas earnings growth is N/A due to the company's inability to generate positive net income in the current period. This divergence between massive revenue growth and negative earnings growth implies that the company is aggressively scaling its sales volume while still grappling with high fixed costs or R&D investments that have not yet been offset by profits. QT Imaging Holdings, Inc. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available resources and retained earnings back into research, development, and commercialization efforts to fuel future expansion. The overall growth and income profile characterizes a high-risk, high-potential venture capital-style investment where returns are expected to materialize from future profitability rather than current cash distributions or revenue stability.